PMID- 24637017
OWN - NLM
STAT- MEDLINE
DCOM- 20141111
LR  - 20211021
IS  - 1872-7972 (Electronic)
IS  - 0304-3940 (Print)
IS  - 0304-3940 (Linking)
VI  - 566
DP  - 2014 Apr 30
TI  - 7,8-Dihydroxyflavone improves motor performance and enhances lower motor neuronal 
      survival in a mouse model of amyotrophic lateral sclerosis.
PG  - 286-91
LID - S0304-3940(14)00171-2 [pii]
LID - 10.1016/j.neulet.2014.02.058 [doi]
AB  - Amyotrophic lateral sclerosis (ALS) is an enigmatic neurodegenerative disorder 
      without any effective treatment characterized by loss of motor neurons (MNs) that 
      results in rapidly progressive motor weakness and early death due to respiratory 
      failure. Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin 
      family known to play a prominent role in the differentiation and survival of MNs. 
      The flavonoid 7,8-dihydroxyflavone (7,8-DHF) is a potent and selective small 
      molecule tyrosine kinase receptor B (TrkB) agonist that mimics the effects of 
      BDNF. In the present study, we evaluated the neuroprotective effects of 7,8-DHF 
      in a transgenic ALS mouse model (SOD1(G93A)). We found that chronic 
      administration of 7,8-DHF significantly improved motor deficits, and preserved 
      spinal MNs count and dendritic spines in SOD1(G93A) mice. These data suggest that 
      7,8-DHF should be considered as a potential therapy for ALS and the other motor 
      neuron diseases.
CI  - Published by Elsevier Ireland Ltd.
FAU - Korkmaz, Orhan Tansel
AU  - Korkmaz OT
AD  - VA Boston Healthcare System, Boston, MA 02130, USA; Neurology and Alzheimer's 
      Disease Center, Boston University School of Medicine, Boston, MA 02118, USA; 
      Physiology and Neurophysiology, Medical Faculty, Eskisehir Osmangazi University, 
      Eskisehir 26480, Turkey.
FAU - Aytan, Nurgul
AU  - Aytan N
AD  - VA Boston Healthcare System, Boston, MA 02130, USA; Neurology and Alzheimer's 
      Disease Center, Boston University School of Medicine, Boston, MA 02118, USA.
FAU - Carreras, Isabel
AU  - Carreras I
AD  - VA Boston Healthcare System, Boston, MA 02130, USA; Biochemistry, Boston 
      University School of Medicine, Boston, MA 02118, USA.
FAU - Choi, Ji-Kyung
AU  - Choi JK
AD  - Radiology, MGH and Harvard Medical School, Boston, MA 02114, USA.
FAU - Kowall, Neil W
AU  - Kowall NW
AD  - VA Boston Healthcare System, Boston, MA 02130, USA; Neurology and Alzheimer's 
      Disease Center, Boston University School of Medicine, Boston, MA 02118, USA.
FAU - Jenkins, Bruce G
AU  - Jenkins BG
AD  - Radiology, MGH and Harvard Medical School, Boston, MA 02114, USA.
FAU - Dedeoglu, Alpaslan
AU  - Dedeoglu A
AD  - VA Boston Healthcare System, Boston, MA 02130, USA; Radiology, MGH and Harvard 
      Medical School, Boston, MA 02114, USA; Neurology and Alzheimer's Disease Center, 
      Boston University School of Medicine, Boston, MA 02118, USA. Electronic address: 
      dedeoglu@bu.edu.
LA  - eng
GR  - R01AG031896/AG/NIA NIH HHS/United States
GR  - I21 BX001624/BX/BLRD VA/United States
GR  - P30AG013846/AG/NIA NIH HHS/United States
GR  - P30 AG013846/AG/NIA NIH HHS/United States
GR  - R01 AG031896/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20140315
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - 0 (7,8-dihydroxyflavanone)
RN  - 0 (Flavanones)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (SOD1 protein, human)
RN  - EC 1.15.1.1 (Sod1 protein, mouse)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - EC 1.15.1.1 (Superoxide Dismutase-1)
RN  - EC 2.7.10.1 (Receptor, trkB)
SB  - IM
MH  - Amyotrophic Lateral Sclerosis/*drug therapy/pathology/physiopathology
MH  - Animals
MH  - Cell Count
MH  - Cell Survival/drug effects
MH  - Dendritic Cells/drug effects/pathology
MH  - Flavanones/*pharmacology/therapeutic use
MH  - Humans
MH  - Mice, Transgenic
MH  - Motor Neurons/*drug effects/pathology
MH  - Motor Skills/drug effects
MH  - Neuroprotective Agents/*pharmacology/therapeutic use
MH  - Receptor, trkB/*agonists
MH  - Spinal Cord/drug effects/pathology
MH  - Superoxide Dismutase/*genetics
MH  - Superoxide Dismutase-1
PMC - PMC5906793
MID - NIHMS576885
OTO - NOTNLM
OT  - 7,8-Dihydroxyflavone
OT  - Amyotrophic lateral sclerosis
OT  - BDNF
OT  - Motor neurons
OT  - TrkB
COIS- Conflict of Interest: The authors declare no competing financial interests.
EDAT- 2014/03/19 06:00
MHDA- 2014/11/12 06:00
PMCR- 2018/04/19
CRDT- 2014/03/19 06:00
PHST- 2013/10/16 00:00 [received]
PHST- 2014/02/13 00:00 [revised]
PHST- 2014/02/26 00:00 [accepted]
PHST- 2014/03/19 06:00 [entrez]
PHST- 2014/03/19 06:00 [pubmed]
PHST- 2014/11/12 06:00 [medline]
PHST- 2018/04/19 00:00 [pmc-release]
AID - S0304-3940(14)00171-2 [pii]
AID - 10.1016/j.neulet.2014.02.058 [doi]
PST - ppublish
SO  - Neurosci Lett. 2014 Apr 30;566:286-91. doi: 10.1016/j.neulet.2014.02.058. Epub 
      2014 Mar 15.